The stock has a 36-month beta value of 0.36. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMMB is 11.87M, and at present, short sellers hold a 1.31% of that float. On May 07, 2024, the average trading volume of CMMB was 217.28K shares.
CMMB) stock’s latest price update
Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB)’s stock price has soared by 15.24 in relation to previous closing price of 0.74. Nevertheless, the company has seen a gain of 25.41% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-24 that TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
CMMB’s Market Performance
Chemomab Therapeutics Ltd ADR (CMMB) has seen a 25.41% rise in stock performance for the week, with a 6.60% gain in the past month and a 40.40% surge in the past quarter. The volatility ratio for the week is 9.42%, and the volatility levels for the past 30 days are at 8.13% for CMMB. The simple moving average for the past 20 days is 20.62% for CMMB’s stock, with a 9.30% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
ROTH MKM, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $7. The rating they have provided for CMMB stocks is “Buy” according to the report published on December 19th, 2023.
CMMB Trading at 15.83% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.88% of loss for the given period.
Volatility was left at 8.13%, however, over the last 30 days, the volatility rate increased by 9.42%, as shares surge +7.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.63% upper at present.
During the last 5 trading sessions, CMMB rose by +25.41%, which changed the moving average for the period of 200-days by -37.29% in comparison to the 20-day moving average, which settled at $0.7101. In addition, Chemomab Therapeutics Ltd ADR saw 67.22% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CMMB
The total capital return value is set at -1.47. Equity return is now at value -90.46, with -73.83 for asset returns.
Based on Chemomab Therapeutics Ltd ADR (CMMB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -310.6. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 1.43.
Currently, EBITDA for the company is -25.33 million with net debt to EBITDA at 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.32.
Conclusion
To sum up, Chemomab Therapeutics Ltd ADR (CMMB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
